Moyu Kimura, Yu Nishiyama, Hiroki Ueda, Akiko Kitajo, Tomoyuki Arimatsu, Mai Kuboki, Atsushi Takahata, Makiko Saito, Chizuko Sakashita, Keigo Okada, Yoshihiro Umezawa, Toshikage Nagao, Masahide Yamamoto, Shuji Tohda, Minoru Tanabe, Takehiko Mori, Ayako Nogami
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by hemolysis, thrombosis, and bone marrow failure. Infection, pregnancy, and surgical operation have the potential to evoke severe episodes of hemolysis and thrombosis. Therefore, the use of an antibody agent against complement component 5 (C5), eculizumab, one day before the operation is recommended. Ravulizumab is a newly approved long-acting antibody agent against C5. Thus, little is known about perioperative management with ravulizumab. We experienced a 43-year-old female patient who safely underwent laparoscopic cholecystectomy under ravulizumab treatment for PNH...
2022: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology